BioAge Labs (BIOA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
21 Apr, 2026Executive summary
Annual meeting scheduled for June 10, 2026, to be held virtually for stockholders of record as of April 16, 2026.
Proxy materials, including the Notice of Meeting, Proxy Statement, and Annual Report on Form 10-K, are available online, with paper copies available upon request.
Voting matters and shareholder proposals
Election of three Class II directors for a three-year term: Patrick Enright, James I. Healy, and Rekha Hemrajani.
Ratification of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Additional business may be considered if properly brought before the meeting.
Board of directors and corporate governance
Board recommends a vote in favor of both director elections and auditor ratification.
Partial view of Summaries dataset, powered by Quartr API
Latest events from BioAge Labs
- BGE-102 achieved up to 86% CRP reduction and strong safety, advancing to Phase 2 trials.BIOA
Study result23 Apr 2026 - Annual meeting to elect directors and ratify auditor, with strong governance and risk oversight.BIOA
Proxy filing21 Apr 2026 - Lead oral NLRP3 inhibitor shows strong Phase 1 results; major trials and $285M cash position.BIOA
Corporate presentation21 Apr 2026 - BGE-102 shows best-in-class potential in inflammation, with pivotal trials and strong financial runway ahead.BIOA
25th Annual Needham Virtual Healthcare Conference16 Apr 2026 - Oral NLRP3 inhibitor shows best-in-class CRP reduction; major clinical readouts expected this year.BIOA
Oppenheimer 36th Annual Healthcare Life Sciences Conference8 Apr 2026 - BGE-102 shows best-in-class anti-inflammatory efficacy for cardiometabolic and ocular diseases.BIOA
Corporate presentation25 Mar 2026 - Strong clinical progress and financing position support multi-year operational runway.BIOA
Q4 202524 Mar 2026 - Lead NLRP3 inhibitor BGE-102 shows best-in-class efficacy in Phase 1, with major milestones ahead.BIOA
Corporate presentation20 Jan 2026 - Azelaprag targets metabolic disease with synergistic weight loss in combination with incretins.BIOA
Jefferies London Healthcare Conference 202413 Jan 2026